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ABSTRACT 
Angiogenesis is involved in the development and progression of many human diseases, 
including cancer, cardiovascular diseases, chronic inflammation, and metabolic 
diseases. Despite differences in microenvironment under various pathological settings, 
angiogenic blood vessels share some common features in numerous diseases. This 
thesis reveals novel molecular mechanisms of angiogenesis in tumors and adipose 
tissues, as well as defining potential therapeutic targets for treatment of cancer and 
obesity-associated metabolic diseases.  
 In Paper I, we showed that PDGF-BB is a tumor-derived vascular remodeling 
factor that promotes tumor growth through activation of stromal fibroblasts and 
perivascular cells in tumor microenvironment. Tumor-derived PDGF-BB activates 
stromal fibroblasts to produce erythropoietin (Epo), which in turn triggers 
extramedullary hematopoiesis thereby enhancing oxygen perfusion in tumor 
vasculatures leading to an accelerated tumor growth rate. Epo is also known as a potent 
angiogenic factor which acts directly on endothelial cells (ECs) to induce tumor 
neovascularization. Therefore, PDGF-BB modulates tumor angiogenesis, vascular 
remodeling and hematopoiesis, via activation of the Epo signaling pathway, thus 
facilitating tumor growth, invasion and possibly reduces drug responsiveness. 
Understanding the role of Epo in promoting tumor growth and angiogenesis not only 
provides novel mechanistic insights into the complex interplay between various 
signaling pathways involved in the stimulation of angiogenesis, but also highlights the 
risk associated with using Epo in treatment of cancer-associated anemia.  
 In Paper II, we used mouse tumor models to propose a novel mechanism 
underlying the combination therapy consisting of anti-angiogenic and 
chemotherapeutic agents commonly used in human patients.  We showed that tumor-
derived VEGF induces severe aplastic anemia in mice, and delivery of 
chemotherapeutics to these tumor-bearing mice led to an earlier demise due to the 
synergistic or additive suppression of bone marrow hematopoiesis by VEGF and 
chemotherapy. Switching to a sequential delivery of anti-angiogenic drugs prior to 
administration of chemotherapeutics drugs resulted in significant recovery of bone 
marrow hematopoiesis, and thus markedly increased tolerance to chemotoxicity. Given 
the fact that a significant number of cancer patients die of chemotoxicity, our findings 
provide an important mechanism in which anti-angiogenic drugs decreases 
chemotoxicity.  
  
 In Paper III, we discuss the novel methods we developed for the study of adipose 
angiogenesis, which are becoming increasingly used by other scientists. In Paper IV, 
we showed for the first time that cold acclimation of mice markedly activates an 
angiogenic phenotype via sympathetic upregulation of VEGF expression. Importantly, 
inhibition of angiogenesis significantly modulates adipose metabolism. This work 
provides the first example where targeting adipose vasculature might provide a novel 
therapeutic approach for the treatment of obesity and metabolic diseases. 
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1 INTRODUCTION  
 
1.1 ANGIOGENESIS  
Angiogenesis, the process of the formation of new blood vessels from existing 
vasculature, is vital in growth and development in both physiological and pathological 
conditions1,2. It can be divided into two types, sprouting and intussusceptive 
angiogenesis2-4. In healthy adults, blood vessels are usually quiescent until activated 
during processes such as wound healing, the female reproductive cycle and 
pregnancy5,6. Angiogenesis is highly governed by the balance of pro-angiogenic 
stimulators and inhibitors, therefore pathological conditions including cancer, diabetes 
and macular degeneration arise when this balance is tipped7,8. The most well-known 
angiogenic stimulators and inhibitors are vascular endothelial growth factor-A (VEGF-
A) and thrombospondins (TSPs), respectively (see 1.1.2.1 and 1.1.3.1).  
 
1.1.1  Angiogenic process   
Angiogenesis is a dynamic and complex process. Angiogenic response is mediated by 
regulators such as growth factors, cytokines, matrix metalloproteinases (MMPs), 
laminins and integrins9-11. Blood vessels are composed of at least two cell types; 1) 
endothelial cells (ECs), which form the lumen of the blood vessels, and 2) mural cells 
that surround the blood vessels to ensure its maturation and the stability.  
Hypoxia is one of the most potent triggers of angiogenesis. When ECs sense a 
low level of oxygen in the local environment, they upregulate hypoxia inducible factor 
(HIF) which in turn upregulate VEGF12,13. Neighboring quiescent ECs respond to the 
VEGF gradient, and compete to become either tip cells or supporting stalk cells. Tip 
cells typically have long filopodia which sprout and migrate towards a high level of 
VEGF concentration, whereas stalk cells that precede tip cells are highly proliferative 
to “push” the tip cells closer to the VEGF gradient14,15. Tip and stalk cell formation are 
highly regulated by VEGF and Notch signaling pathways. VEGF binds to vascular 
endothelial growth factor receptor-2 (VEGFR-2) on tip cells and stimulates delta-like 4 
production16,17. Delta-like 4 then binds to transmembranal Notch receptors on 
nonsprouting stalk cells. Simultaneously, when the dynamic angiogenic response is 
triggered, anti-angiogenic factors such as endostatin, angiostatin and TSP are 
upregulated18-21. Activated ECs also secrete MMPs to breakdown the basement 
membrane of blood vessel walls, thereby allowing ECs to proliferate and migrate11,22. 
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The sprouting tip cells proliferate to form a capillary tube through anastomosis. The 
newly formed lumen allows blood flow that provides oxygen to the hypoxic tissue. 
Increased oxygenation cancels the hypoxia signal, thereby reducing VEGF 
secretion12,13,23. Meanwhile, tip cells secrete platelet derived growth factor-BB (PDGF-
BB), which recruits platelet derived growth factor receptor-beta (PDGFR-β) positive 
mural cells to ensure maturation and stability of the newly formed capillary24,25.  
 
1.1.2 Angiogenic stimulators 
Positive regulators of angiogenesis can range from growth factors to cytokines that 
switch on the angiogenesis process in quiescent vessels1,2,5,6,19. Many angiogenic 
stimulators have been purified and characterized, including VEGF (see 1.1.2.1), PDGF 
(see 1.1.2.2), Angiopoietin (Ang)/Tie2 (see 1.1.2.4), erythropoietin (Epo) (see 1.1.2.3), 
hepatocyte growth factor, fibroblast growth factor and MMPs. 
 
1.1.2.1 Vascular endothelial growth factor (VEGF) 
VEGF is one of the best-characterized angiogenic growth factors involved in 
regulations of both physiological and pathological angiogenesis23. In 1983, Senger et al. 
purified a 38 kDa protein known as vascular permeability factor from pigs’ liver tumor, 
which was later determined to be similar to VEGF purified by Ferrara et al. in 198926,27.  
 
Figure A. The VEGF family and VEGF receptors 
The VEGF family of proteins consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D 
and PlGF28-30. VEGF proteins bind to the tyrosine kinase receptors (TKRs), VEGFR-1, 
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-2, and -3, triggering downstream signaling cascades that stimulate growth, 
proliferation, and migration of ECs28-30 (Figure A). Different VEGF-A exists in 
isoforms as a result of alternative splicing. VEGF-A binds to VEGFR-1, VEGFR-2, 
neuropilin 1 (NP1) and neuropilin 2 (NP2). VEGFR-1 and VEGFR-2 are primarily 
expressed on ECs and other cell types including neurons and hematopoietic stem cells. 
VEGF-A binds VEGFR-1 with higher affinity, but most of the biological effects 
are exerted through interaction with VEGFR-2 due to the weaker kinase activity of 
VEGFR-1. It is therefore postulated that VEGFR-1 acts as a decoy receptor that 
reduces binding of VEGF-A to VEGFR-2, hence dampening the angiogenic response. 
While VEGFR-1 knockout mice are embryonic lethal due to defects in hemangioblast 
differentiation and impaired vascular formation, VEGFR-2 knockout mice are 
embryonic lethal due to defects in hematopoietic precursors31-33. The expression of 
VEGF is driven by environmental cues such as hypoxic conditions under which 
hypoxia inducible factor (HIF) is upregulated, as well as factors such as leptin, insulin, 
oncogenes and tumor suppressor genes13,23,34,35. 
                        
1.1.2.2 Platelet derived growth factor (PDGF)  
Members of the PDGF family and their receptors, PDGFRs, have been reported to 
influence tumor growth and invasive progression through interaction of tumor cells and 
their surrounding stroma24.  
 
Figure B. The PDGF family and PDGF receptors 
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 The PDGF family consists of five homodimers or heterodimers, PDGF-AA, 
PDGF-BB, PDGF-AB, PDGF-CC and PDGF-DD which bind to their respective TKRs 
(Figure B), PDGFR-alpha (PDGFR-α) and PDGFR-beta (PDGFR-β), thereby 
activating downstream signaling pathways resulting in the modulation of ECs survival, 
growth and migration25,36. 
 PDGF-BB/PDGFR-β signaling pathway is crucial in mediating pericyte 
recruitment to blood vessels37,38. PDGF-BB is secreted as a homodimer by ECs of 
sprouting tip cells, which recruit PDGFR-β positive pericyte onto the nascent 
vasculature. The recruitment of pericytes to blood vessels is essential in maintaining the 
normal function of vessels. Lack of pericyte coverage, as seen in PDGF-BB or 
PDGFR-β deficient mice, results in unstable, leaky vessels and irregular vascular 
network38,39. Increased PDGF and PDGFR expression have been reported in different 
cancer types including glioma, prostate cancer and pancreatic cancer40,41. 
 The PDGF/PDGFR signaling cascade has been shown to play an essential role in 
invasion and metastasis by promoting epithelial mesenchymal transitions in colorectal 
and breast cancers42,43. Nilsen et al. reported that coexpression of PDGF-BB and 
fibroblast growth factor results in a synergistically induced tortuous vascular network44. 
PDGF-BB can also induce angiogenesis via upregulation of Epo (see Paper I). Anti-
PDGF drugs are currently used in the clinic for treatment of leukemia and 
mastocytosis45,46. However, it was shown in a recent finding that the anti-PDGF drug 
imatinib mesylate inhibited PDGF-BB/PDGFR-β signaling cascade in high PDGF-BB 
producing tumor, but promoted the repulsion of pericytes from tumor vessels in low 
producing tumor, causing implications in tumor invasion47. Therefore, anti-PDGF drug 
treatment should be administered based on PDGF-BB levels in patients.  
 
1.1.2.3 Erythropoietin (Epo) 
Epo, a cytokine hormone with a molecular weight of 34 kDa, controls erythropoiesis, 
the process of red blood cell (RBC) production. The kidney is the primary source of 
Epo48. Epo binds to Epo receptor (EpoR) on erythroid progenitors cells triggering 
downstream signaling pathways resulting in the proliferation, maturation and 
differentiation of RBCs49. In the clinic, recombinant human Epo (rhEpo) is used as a 
treatment regimen against anemia observed in patients suffering from kidney disease, 
HIV, and in cancer patients receiving chemotherapeutic drugs50,51. Epo delivery 
improves the level of RBC, thereby improving oxygenation51,52. However, the 
administration of rhEpo to patients should be monitored closely as EpoR is also found 
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on different cell types, and the Epo/EpoR axis has been shown to induce proliferation, 
angiogenesis, and inhibit apoptosis thereby supporting tumor invasion49,53,54.  
 
1.1.2.4 Angiopoietin and Tie receptors  
Ang ligands and Tie receptors play essential roles in vascular development, remodeling 
and maturation. The Ang family consists of Ang-1 and Ang-2. Ang-1 acts as an agonist 
while Ang-2 acts as an antagonist for the Tie2 receptor55. Ang-1 binds to Tie2 receptor 
on ECs to induce autophosphorylation of Tie2, which stimulates ECs survival and 
angiogenesis. On the other hand, Ang-2 binds to Tie2 receptors on ECs with similar 
affinity to that of Ang-1, resulting in competitive binding and inhibition of vascular 
maturation and stabilization. Ang-1, Ang-2 and Tie2 receptors are crucial in early 
vascular development, and deletion of Ang-1, Ang-2 or Tie2 causes defects in 
embryonic vascular development56,57.  
 
1.1.3 Angiogenic inhibitors  
Angiogenic inhibitors can be categorized into endogenous and exogenous. Endogenous 
inhibitors include soluble VEGFR-1, Ang-2, TSP, angiostatin, integrins and endostatin, 
which exert their effect through inhibition of ECs survival, proliferation and 
migration10,18-21,55,58. Angiostatin and endostatin seem to be the most promising 
amongst all endogenous inhibitors, however, the beneficial outcome of administering 
exogenous angiostatin and endostatin can be difficult to predict20,21,58,59. 
 
1.1.3.1 Thrombospondin (TSP) 
TSP was the first endogenous angiogenesis inhibitor reported in tumors60. The TSP 
family is comprised of five multimeric glycoproteins, which regulate cell-cell and cell-
matrix interactions18. In the tumor environment, TSP-1 and TSP-2 serves as potent 
endogenous inhibitors of angiogenesis by activating transforming growth factor beta, 
thus suppressing tumor angiogenesis61. TSP-1 binds to VEGF, which prevents the 
release of VEGF from extracellular matrix. Deletion of TSP-1 results in enhanced 
angiogenesis62. 
 
1.1.3.2 Angiostatin and Endostatin  
Several angiogenic inhibitors are proteolytic fragments of larger proteins. For example, 
angiostatin is a fragment of plasminogen and was first isolated in 1994 from serum and 
urine of tumor-bearing mice21. Angiostatin has been reported to bind to several 
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receptors on the ECs including adenosine triphosphate synthase, annexin II angiomotin 
and integrin αvβ321.Angiostatin was reported to inhibit tumor angiogenesis and growth 
by inhibiting ECs migration, proliferation and via induction of apoptosis58. 
 Endostatin, a 20 kDA protein fragment of collagen XVII, is a member of the 
endogenous anti-angiogenic factors. The naturally produced endostatin, first described 
by O’Reilly and Folkman in 1997, was reported to inhibit angiogenesis and shrank 
tumor growth significantly20. Endostatin inhibits angiogenesis by downregulating 
pathways involving tumor necrosis factor-alpha, nuclear factor kappa B and ephrin 
which results in inhibition of survival and migration of ECs. This led to the belief that 
endostatin was the “ideal anti-cancer weapon” to eradicate cancer. In 1998, Dr James 
Watson said: “Judah Folkman is going to cure cancer in two years.” However, after a 
phase II trial, it was concluded that endostatin did not result in a significant tumor 
regression in patients with advanced neuroendocrine tumors59,63. In conclusion, the use 
of these endogenous inhibitors warrants further investigations.  
 
1.2 CANCER  
1.2.1 Tumor angiogenesis  
In 1971, Dr Judah Folkman, a prestigious cancer surgeon, revolutionized our 
understanding of cancer with his remarkable breakthrough when he coined the concept 
of tumor angiogenesis – the process of blood vessels formation in a tumor7. He 
postulated that in order for a tumor mass to grow beyond 2 to 3 mm3, new blood 
vasculature (neovascularization) is required to supply oxygen and nutrients, as well as 
remove metabolic waste products1. Therefore, anti-angiogenesis can be an effective 
therapy against tumor growth if deprivation of tumor cells from oxygen and nutrients is 
effectively achieved64,65. Since then, it has stirred immense interest in the research 
community, and many therapeutic drugs have been developed to target angiogenesis 
dependent diseases including cancer, ophthalmic diseases, arthritis, psoriasis, obesity 
and obesity-related metabolic diseases5-8,19,65,66. 
 Cancer is a complex disease. Tumor angiogenesis – the sophisticated process 
employed by cancer cells to grow blood vessels to support their own growth – is as 
intricate as a Gordian knot. Angiogenesis is essential, and crucial for physiological 
processes including regulation of fetal development, the menstrual cycle, and wound 
healing5-7,67,68. Similar to healthy tissues, the growth and progression of cancer is highly 
dependent on angiogenesis1,7,8,69. 
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 Tumor angiogenesis is one of the most important steps in mediating tumor 
progression and development. When the tumor mass is small, tumor cells can rely 
solely on the host blood vessels for oxygen, nutrients and the removal of metabolic 
waste products. However, angiogenesis is required to further support its growth beyond 
2 to 3 mm3 1,7,8. Tumor cells trigger angiogenesis via sprouting angiogenesis and 
intussusceptive angiogenesis70,71. Unlike blood vessels in healthy tissues, tumor vessels 
are usually highly dilated. Tumor vessels are also highly disorganized, and arterioles, 
venules and capillaries become difficult to classify. Tumor vessels are highly 
permeable and leaky due to increased endothelial fenestrations72. These abnormal 
characteristics of tumor vessels caused improper delivery of oxygen and nutrients 
resulting in a hypoxic environment, which further activate the angiogenic cascade12,13 
(see 1.1.1). Intussusceptive angiogenesis, also known as vessel splitting, is initiated 
when ECs from opposite sides of the capillaries protrude towards each other, which 
creates a lumen and further fuses to complete the formation of a functional 
neovasculature71. 
 Cancer cells fully exploit the blood vessels to succinate their survival and mediate 
their progression and dissemination67,68,73,74. Blood vessels not only provide the 
necessary nutrients to support tumor growth, they also act as a passageway for cancer 
cells to leave the primary site, enter the circulation and metastasize to a new site67,68,73,74. 
Therefore, understanding the role of angiogenesis in cancer development has pivotal 
role in the circumvention of cancer65.  
 
1.2.2 Cancer  
Cancer is one of the major causes of mortality and morbidity worldwide, where one in 
four individuals would be affected. The World Health Organization (WHO) reported in 
2008 that approximately 7.9 million deaths (13% of all death) were due to cancer. The 
WHO also projected that the number of deaths from cancer will increase 45% from 
2007 to 2030. Fortunately, with the advancement in modern science and technology, 
we are getting closer to unravel this complex disease. However, continuous effort is 
required to understand this complex disease as cancer cells develop resistance 
mechanisms to therapy, which is one of the major hurdles in the treatment of cancer.  
 
1.2.3 Cancer progression   
Cell division and proliferation are usually tightly controlled and highly governed by 
DNA damage repair genes, apoptotic genes, tumor suppressors and immune cells. 
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When these processes become unregulated, it results in an abnormal uncontrolled cell 
growth, which is a characteristic of cancer8,67,68. The progression and development of 
cancer is a long process that begins when a cell in a tissue or organ evades the usual 
process of apoptosis and continues to multiply uncontrollably. Perpetual propagation of 
these cells result in cancer. Exposure to chemical carcinogens or ionizing radiation as 
well as infection by viruses such as human papillomavirus, hepatitis B and C, and 
Epstein-Barr virus can induce genomic instability through accumulation of 
consequential mutations75-77. 
 The word “tumor” is derived from the Latin “tumere”, which means to swell. 
Tumor can be classified as benign or malignant. Tumors that are not cancerous are 
classified as benign. Fortunately, not all tumor or neoplasm masses develop or progress 
into cancer. This form of tumor is not life threatening, but may pose problems to local 
tissue due to the pressure they exert on neighboring tissues and organs. Malignant 
cancer on the other hand is life threatening as they not only invade the local primary 
site, but also extravasate to distal organs by metastasis67,68,73. Cancer cells are malleable 
and can adapt to best exploit the host and eventually destroy it. The process of 
metastasis is a long process that involves different steps: Malignant cancer cells have to 
first intravasate into the blood stream, survive in the blood stream, invade a new site 
and start proliferating in the new niche67,68,73. 
 It is well accepted that tumor environment is complex due to the interactions of 
various cell types such as fibroblasts, ECs, mesenchymal and immune cells, each of 
which play their part in tumor growth, development and progression by secreting a 
myriad of cytokines and growth factors into the tumor microenvironment67,68,72-74,78. 
Cancer cells that are capable of developing resistance to drugs are probably assisted by 
various cell types in the tumor microenvironment79,80. It was reported that only 
minority of cancer deaths is caused by the primary tumor, whereas most cancer patients 
die from metastasis at the later stages of their malignancy81. Cachexia manifestation in 
cancer patients contributes to 20% of cancer deaths82. Taken together, this suggests that 
an “off tumor target regimen” could be a better approach to circumvent and improve 
the survival of these cancer patients83.  
 
1.2.4 Anti-angiogenic therapy in cancer  
To date, many anti-angiogenic drugs have been developed and approved by the Food 
and Drug Administration (FDA) for the treatment of many types of cancer based on the 
humdinger concept proposed by Dr Judah Folkman1,7,64. Anti-angiogenic drugs can be 
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classified into subtypes: 1) Monoclonal antibodies such as bevacizumab (see 1.2.4.1), 2) 
ligands targeting the VEGF pathway such as aflibercept and ramucirumab, 3) small 
molecule tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (see 1.2.4.2), 
sunitinib (see 1.2.4.3), sorafenib, pazopanib, and 4) inhibitors of mTOR kinases such as 
everolimus. Anti-angiogenic drugs are commonly administrated in combination with 
conventional chemotherapy84 (Figure C).  
 
Figure C. Anti-angiogenic drugs targeting VEGF and VEGF receptors 
Similar to most drugs, anti-angiogenic drugs cause side effects including 
gastrointestinal perforation, hypertension and proteinuria65 (Figure D). It is proposed 
that anti-angiogenic drugs to normalize blood vessels to allow higher efficacy of drug 
delivery85. In Paper II, we hypothesized that sequential delivery of anti-angiogenic drug 
prior to chemotherapy could protect bone marrow against chemotherapy-induced 
deficits in hematopoietic regeneration. 
 
Figure D. Common side effects of anti-angiogenic therapy 
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1.2.4.1 Bevacizumab  
Bevacizumab, also known as Avastin® (Genentech) is the first humanized monoclonal 
antibody, which recognizes and binds specifically to VEGF86 (see 1.1.2.1). 
Bevacizumab prevents VEGF from binding to receptors, thereby inhibiting the 
downstream signaling cascade, preventing angiogenesis and depriving tumor cells from 
oxygen and growth factors needed for growth86. Bevacizumab was first approved in 
2004 by the FDA as a first-line therapy for metastatic colorectal cancer (MCC) in 
combination with chemotherapy drug84,87. Bevacizumab administration to MCC 
patients improved overall survival by five months and progression free survival for four 
months. In 2006, bevacizumab was approved in non-small cell lung cancer used in 
combination with chemotherapy, carboplatin and paclitaxel88. In 2008, FDA granted 
the use of bevacizumab in metastatic HER2-negative breast cancer89. Bevacizumab was 
further approved in 2009 for patients with metastatic renal cell carcinoma90.  
 It looked promising until 2011, when FDA withdrew the use of bevacizumab in 
metastatic HER2-negative breast cancer. Bevacizumab, like all other drugs, has side 
effects, the most serious of which includes gastrointestinal perforation, hemorrhage, 
hypertension and incomplete wound healing91. Unfortunately, in the case of metastatic 
breast cancer, the side effects of bevacizumab outweighed the beneficial effects 
observed in these cancer patients92.  
 
1.2.4.2 Imatinib mesylate 
Imatinib mesylate, also known as Gleevec® or STI571 (Norvatis) is a small molecule 
TKI. Imatinib mesylate prevents proliferation by competively binding to tyrosine 
kinases, hence preventing the binding of substrates to the kinase sites. Imatinib 
mesylate binds to tyrosine kinase such as bcr-abl, c-kit and PDGFR93-95. It was first 
approved by the FDA in 2002 for the treatment of gastrointestinal stromal tumors and 
subsequently, approved for the treatment of leukemia and mastocytosis. Imatinib 
mesylate causes adverse effects including diarrhea, hypertension, hand-foot skin 
reaction and skin rash96.  
 
1.2.4.3 Sunitinib malate 
Sunitinib malate, or Sutent® (Pfizer) is a TKI approved by the FDA for the treatment of 
gastrointestinal stromal tumor, pancreatic cancer and renal cell carcinoma97-99. Sunitinib 
malate targets the intracellular domain of tyrosine kinase including VEGFRs, PDGFRs, 
c-kit, Ret, CSF-1R and Flt-393,100. Sunitinib is approved by the FDA for the treatment 
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of gastrointestinal stromal tumor intolerant to imatinib mesylate. Adverse effects of 
sunitinib includes gastrointestinal toxicities, hypertension, hair depigmentation and 
dermatologic sensitivity93.  
 
1.2.5 Chemotherapy  
Chemotherapy primarily aims to kill rapidly dividing cells such as cancer cells by 
targeting their RNA and DNA, hence preventing their division101. Chemotherapy can 
be categorized into different classes based on the mechanisms to kill cancer cells and 
their chemical structure (i.e. platinum-based drugs, taxanes and vinca alkaloids)102. 
Most chemotherapy belongs to a class of drugs known as alkylating agents, which 
prevent cancer cells from growing and thus killing them. However, chemotherapy is 
unable to differentiate between dividing cancerous and noncancerous cells, therefore 
resulting in adverse effects. As many chemotherapeutic drugs induce severe 
impairment in bone marrow hematopoietic regeneration, most chemotherapy is given as 
a combination therapy with other anti-cancer drugs103,104. In this thesis, we set out to 
ask if anti-angiogenic drugs administered as neoadjuvant threapy to cancer-induced 
bone marrow impaired patients would first allow the bone marrow to have time to 
recover before further exposure to chemotherapy.  
 
1.2.5.1 Carboplatin  
Carboplatin, also known as paraplatin, is a cisplatin that binds to DNA and kills 
proliferating cancer cells101. Carboplatin was approved by the FDA to use as a single 
agent therapy or in combination with other drugs for the treatment of non-small cell 
lung cancer and recurrent ovarian cancer105,106. Common side effects of carboplatin 
include decrease in RBC counts, low platelet count and neutropenia which causes 
anemia, increased risk of bleeding and increased risk of infections, hair loss, nausea and 
vomiting103,104.   
 
1.2.5.2 Cyclophosphamide  
Cyclophosphamide or more commonly known as CTX has been approved for the 
treatment for lymphoma, leukemia, multiple myeloma, breast and ovarian cancers107. 
CTX elicits its effect by crosslinking with DNA therefore inhibiting cell proliferation. 
CTX causes possible adverse effects such as increased risk to infection due to decrease 
in white blood cell (WBC) counts, bleeding in the bladder, hair loss, nausea and 
vomiting103,104,107.  
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1.3 ADIPOSE TISSUE  
Obesity and over weight are first world health epidemics that requires immediate 
attention due to the implicated major chronic diseases that are tagged along with this 
metabolic disorder caused by excessive fat (adipose tissue) accumulation35,108,109. 
Obesity and overweight is also escalating in the developing countries. The prevalence 
rate of obese individuals has escalated at least two-folds within the last 30 years. 
According to the WHO, an individual is classified as overweight when body mass 
index (BMI), calculated by weight in kilograms divided by the square of height in 
meters, is equal to or more than 25; with a BMI of more than 30, an individual is 
classified as obese. 
The WHO projected that in 2015, approximately 2.3 billion adults will be 
overweight and 700 million will be obese. The fact that childhood obesity has tripled in 
the past 30 years is becoming an urgent issue to tackle. Childhood obesity predicts 
serious and imminent problems on physical and psychological health. Excessive 
accumulation of fat from high food intake and low physical activities attributes to 
health impairing diseases such as type II diabetes, cardiovascular diseases, stroke and 
certain types of cancers35,110-114. Therefore, therapeutic intervention of obesity requires 
immediate attention.  
 
1.3.1 White adipose tissue and brown adipose tissue  
Similar to other organs, the growth and regression of adipose tissue is highly regulated 
by blood vessels115. Adipose tissue in humans and other mammals can be broadly 
categorized into white adipose tissue (WAT) and brown adipose tissue (BAT). 
Substantial evidence now suggests a third type of adipose tissue, the brite (brown-in-
white) / beige adipose tissue110-112. WAT is present in the subcutaneous and visceral 
abdominal fat, stores energy as large fat droplets in the form of triglycerides, which 
upon lipolysis releases fatty acids and glycerol. Aside serving as mechanical support 
for several organs in our body, WAT is also a rich source of adipokines35,109,113,116. 
 In contrast, BAT, present in smaller amount in the cervical and supraclavicular 
areas, consists of multilocular droplets that are rich in mitochondria (see 1.3.3). BAT is 
essential for facultative and adaptive thermogenesis, and is believed to be promising for 
combatting obesity117-119. Accumulation of visceral fat is considered to be more harmful 
due to its high correlation with metabolic disorders such as glucose intolerance, 
hypertension, dyslipidemia and insulin resistance120.   
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1.3.2 Vascular functions and adipose derived factors  
WAT and BAT are highly vascularized, with almost each adipocyte typically 
surrounded by a blood vessel, which provides oxygen and nutrients for growth and 
maintenance, as well as the removal of metabolic waste products35,121,122. Most people 
are more familiar with WAT – the blob or rather blobs of unwanted fat accumulation in 
undesirable places of the body, (something) we yearned to get rid of – without fail 
appears on our top ten New Year’s resolution. And if they are gone, oh good riddance, 
we praise. The intimate interaction between adipocyte and blood vessels is crucial for 
the regulation of homeostasis in the adipose tissue35,113-115,122. Vascular density in the 
adipose tissue is highly correlated to the metabolic statues of the adipose tissue; BAT 
has significantly higher blood vessel density to cope with its high metabolic demands, 
whereas the metabolically less active WAT is also less vascularized. Blood vessels are 
also sources of growth factors, cytokines, hormones, stem cells and inflammatory cells 
that are essential for the maintenance of the adipose tissue35,109,113-116 (Figure E).   
 
 Figure E. Vascular functions and adipose-derived factors (adapted from Angiogenesis in 
Adipose tissue, Springer book, 2013). 
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 Adipose tissue is one of the most plastic organs in the body. Its capability to 
expand and regress up to 10-fold throughout adulthood is highly dependent on blood 
vessels, suggesting that adipose tissue has the ability to maintain and also to recruit new 
vessels115,116. Adipose tissue is now accepted as an endocrine organ, which secretes a 
myriad of cytokines and growth factors – collectively known as adipokines109. Apart 
from adipocytes, adipose tissue comprised of ECs, preadipocytes, macrophages, 
lymphocytes and fibroblasts. The hypoxic conditions resulting from the expansion of 
adipocytes drives HIF-1α, which further induced expression of VEGF, leptin, tumor 
necrosis factor-alpha, and plasminogen activator inhibitor-1, thereby initiating 
neovascularization12,35,113,114,116. Adipose tissue produces angiogenic inhibitors such as 
adiponectin, which inhibits angiogenesis. Adiponectin expression levels negatively 
correlate with obesity. Adipose tissue also produces other inhibitors such as endostatin, 
TSP-1 and VEGFR-2123,124.  
 
1.3.2.1 VEGF in adipose tissue homeostasis  
VEGF is highly expressed in adipose tissues and function as the main angiogenic 
response. Adipocytes and resident macrophages have been reported to be the main 
sources of VEGF34,125. The expression and production of VEGF in adipose tissue is 
driven mainly by insulin and hypoxia34,126. Genetically modified mouse with adipose 
tissue specific VEGF knockout (aP2-Cre) resulted in abnormal decrease in blood 
vasculature in adipose tissue127. It was reported that blockade of VEGF or VEGFR-2 
function inhibits WAT expansion in diet-induced obesity (DIO)128. Independent 
research groups reported that hypoxia is experienced in obese individuals during the 
expansion of adipocytes (hypertrophy), which in turn stimulates angiogenesis126. 
However, Pasarica et al. demonstrated that VEGF level does not correlate with 
expanding adipocytes in human129. Modulation of VEGF in adipose tissues could be a 
therapeutic regimen for treatment of obesity and obesity-related metabolic 
diseases122,130.  
 
1.3.3 Brown adipose tissue and non-shivering thermogenesis  
When mammals are exposed to cold, the initial mechanism is to shiver to defend their 
body temperature119. However, with time (adaptive thermogenesis), they will recruit 
non-shivering thermogenesis (NST), which increases their metabolism and heat 
production through activation of BAT131. In mice, norepinephrine (NE) is injected to 
investigate NST that originates from BAT (Paper IV). Cold exposure stimulates 
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sympathetic activation and release of NE, which then binds to the adrenergic receptors 
on plasma membrane on BAT. The downstream signaling activated as a result triggers 
the lipolysis of triglycerides into free fatty acids and glycerol. Free fatty acids then bind 
to uncoupling protein 1 (UCP1) stimulating respiration in the mitochondria. BAT, 
differs from its counterpart WAT, by its unique ability to burn fat to produce heat upon 
stimulation119.  
 UCP1 is a transmembrane protein, virtually exclusively expressed in the inner 
membrane of mitochondria of BAT132. BAT has been reported to be the only organ in 
the body that is capable of adaptive thermogenesis119. Ablation of UCP1 results in 
obese phenotype in mice demonstrating the importance of UCP1 in regulating diet-
induced adrenergic thermogenesis133. Recently publications also show the importance 
of BAT in regulating glucose homeostasis and plasma triglyceride clearance134,135. BMI 
was reported to negatively correlate to the amount of BAT. Taken together, these 
suggest that the activation of BAT in obese individuals may be a therapeutic 
intervention for obesity since merely 40-50 g of fully activated BAT is able to burn up 
to 4 kg of WAT in a year136,137.  Despite all the investigations on BAT and 
thermogenesis, little is known about the role of blood vessels in regulating this highly 
metabolic tissue.   
 
1.3.3.1 Refuting the dogma – Existence of brown adipose tissue in human adults 
Research of BAT can be dated back to the 1960s where several groups had described 
the role of BAT in cold-induced thermogenesis in small mammals138. After 40 years, 
the longstanding dogma that adult human does not have functional BAT was being 
definitively refuted in 2009. BAT is believed to play an essential role only in neonates 
but not in adults. Interestingly, in 2009 three independent back-to-back publications in 
NEJM demonstrated the existence of functional BAT through [18F]fluorodeoxyglucose 
(FDG) positron emission tomography and computerized tomography (PET-CT) – 
usually used to detect cells or tissues with high uptake of glucose. Cypess et al., van 
Marken Lichtenbelt et al. and Virtanen et al. used FDG PET-CT which demonstrated 
an increased glucose uptake in BAT of human adults exposed to cold (exposure at 16˚C 
for 2 hours)136,139,140. Virtanen et al. reported up to 15-fold increase in the glucose 
uptake in cold-exposed adults, and detection of the BAT specific UCP1 protein usually 
specific to the BAT was increased in the WAT of these cold-exposed human adults139. 
The detection of active FDG uptake in BAT of human adults indeed revoked a surge of 
interest in the scientific community to further elucidate methods to demonstrate the 
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activity of BAT in adult human, with the hope of exploiting metabolic properties of 
BAT in order to generate novel therapeutic treatments for obesity. Since then, many 
researchers have been demonstrated the possibility to increase BAT or brite adipose 
tissue activity in human adults110-112,141-143.  
 Yoneshiro et al., reported that cold exposure (19˚C) of healthy young for 6 weeks, 
resulted in an increase the FDG uptake in the supraclavicular BAT demonstrating BAT 
activity. This increased in cold-induced increments of energy expenditure thereby 
contributing to the reduction in body fat mass110,144,145. Interestingly, dietary intake of 
capsinoids mimics the effect of cold exposure, in increasing BAT activity143. 
 A recent study showed that administration of high concentration of ephedrine, an 
adrenergic agonist, increases the activity of BAT in lean individuals but not in obese 
individuals146. However, adrenergic agents when used in high dosages caused side 
effects including high blood pressure and heart rate. Therefore, the use of adrenergic 
agents such as ephedrine as an anti-obesity drug still requires further investigations.  
 
1.3.4 Brite adipose tissue  
The adipose tissue scientific community has made concerted efforts to increase the 
activity of the BAT (or UCP1 expression) in human adults, and to characterize 
beige/brite adipose tissue which regulate energy expenditure, in hope to combat 
obesity110,142,145,147. Brown adipocytes seem to originate from the same precursor as the 
skeletal muscle that expresses the muscle factor Myf5, while white adipocytes originate 
from Myf5-negative precursors148. However, the origin of the brite adipocytes warrants 
further investigations even though they seem to originate from the Myf5-negative 
precursors111,112. Yoneshiro et al. reported that BAT activity decreases with age, and 
could be responsible for age related fat accumulation110. Rajakumari et al. discovered 
that early B cell factor-2 could switch on white to brown-like transition149. 
Overexpressing early B cell factor-2 in WAT resulted in increased metabolism in mice, 
demonstrating increased energy expenditure149. Another group demonstrated that mice 
with ablation of type 1A BMP-receptor were born with deficiency of BAT, but were 
still capable of maintaining normal temperature and preventing DIO by white to brite 
transition150. It was reported that the activity of sirtuins deacetylates peroxisome 
proliferator-activated receptor-gamma induced white to brown-like transition leading to 
increased metabolic activity151. 
Brite adipocytes can also be induced by chronic cold exposure (Paper IV) or 
through stimulation of β-adrenergic receptor agonists110,131,143. Upon chronic cold 
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exposure, these brite adipocytes upregulated expression of genes like Ucp1, Cidea, 
Cox7a1, which are otherwise specific to BAT152,153. Importantly, changes in the 
vascular system accompany the white to brite transition. Many angiogenesis related 
genes are upregulated during the transition of white to brite thereby stimulating 
angiogenesis to support the high metabolic demand (Paper IV). We speculate that 
increased vascularization in cold-induced transition further provide more angiogenic 
growth factors, cytokines, hormones, stem cells and inflammatory cells, which support 
the survival and maintenance of adipose tissue.  
 
1.3.5 Potential anti-obesity therapies   
Many research groups have shown that anti-angiogenic drugs such as TNP-470, 
angiostatin, endostatin, and anti-VEGF agents can inhibit adipose tissue mass in both 
DIO and genetically modified mouse models122,130,154. TNP-470, derived from 
fumagillin is an anti-angiogenesis inhibitor, which inhibits ECs proliferation, cell 
migration and angiogenesis. It has been reported to also inhibit DIO in genetically 
modified leptin deficient ob/ob mice models by reducing caloric intake and increasing 
energy expenditure. TNP-470 treatment decreases circulating levels of low-density 
lipoprotein and cholesterol. TNP-470 treatment also increases insulin sensitivity, 
suggesting that anti-angiogenic inhibitors might be able to prevent the development of 
type II diabetes130. Despite the benefits, TNP-470 caused neurotoxic effect in mice, 
therefore the use of TNP-470 as an anti-obesity drug in human needs further 
investigations.  
 Studies have shown the presence of functional BAT in lean human adults after 
cold exposure110,136,144,145 Therefore, finding methods to increase the activity of BAT or 
increasing WAT to brite transition could be an important strategy against obesity. We 
were interested to investigate the role of blood vessels in modulating WAT to brite 
adipose tissue transitions. Would combination therapy of anti-angiogenic drugs therapy 
and stimulation of WAT to brite transition be an effective therapy to combat obesity 
and its related metabolic diseases?  
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2 AIMS 
The overall aim of this thesis was to elucidate the roles of angiogenesis in both tumor 
development and adipose tissue metabolism, by exploring the potential interventions 
for treatment.  
 
The specific aims were:  
• To investigate the role of angiogenic factor, PDGF-BB in the tumor 
environment  
• To study the systemic effect of angiogenic factor, VEGF-A, and to propose a 
neoadjuvant delivery of anti-angiogenic drug before chemotherapy in tumor 
• To investigate the angiogenic switch in mediating white to brite adipose tissue 
transition 
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3 METHODS 
In this section, I will discuss some of the key methods used in this thesis (detailed 
experimental procedures are elaborated in materials and methods of the constituent 
papers). The key and limiting factors will also be discussed in this section.  
 
Mouse tumor model – syngeneic and xenograft  
To investigate tumor angiogenesis and the interaction of different growth factors in the 
tumor microenvironment, we used syngeneic and xenograft mouse models (Paper I, II). 
Prior to tumor inoculation, mouse or human cell lines were cultured in DMEM or 
RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and 1% 
penicillin streptomycin at 37˚C at 5% CO2. At approximately 80% confluence, cells 
were washed twice with phosphate buffered saline (PBS) and trypsinized in 0.25% 
trypsin. Trypsin was neutralized with medium containing 10% FBS and cell suspension 
was well mixed and counted using a hemocytometer. Cells were resuspended in PBS 
and approximately one million cells were injected into the dorsal subcutaneously to 
C57 black 6 (C57/Bl6) or severe combined immunodeficiency (SCID) mice. Tumor 
size, once palpable was measured every other day with a vernier caliper. Tumor volume 
was calculated using the formula, width2 × length × 0.52155. In blockade experiments, 
PDGFR-α (IH3) or PDGFR-β (2C5) (0.8 mg per mouse, three times a week, i.p., 
Imclone) antibodies, STI571 (1 mg per mouse, daily, i.p., LC laboratories), EPO 
neutralizing antibody (0.2 mg per mouse, three times a week, i.p., R&D systems) were 
administrated on day five after tumor inoculation (Paper I). CTX (62.5 mg/kg, i.p., 
Sigma-Aldrich), carboplatin (50 mg/kg, i.p., Hospira) or sunitinib malate (60 mg/kg, 
p.o., LC Laboratories) were administrated when tumor volume reached 0.5 cm3 (Paper 
II). VEGFR-1 (MF1) or VEGFR-2 (DC101) (800 µg per mouse, i.p., Imclone) were 
administrated twice a week for four weeks (Paper IV).  
 
Mouse cold adaptation assay  
Prior to exposure of mice to 4˚C (cold), it is critical to adapt mice at 18˚C for at least 
one week. The adaptation period is dependent on the mouse strains (Paper IV). 
Thermoneutral zone is the temperature where the resting basal metabolic rate is at the 
lowest maximum gradient to maintain functionality of different organs. The 
thermoneutral zone in mice is approximately 30˚C; therefore sudden exposure of mice 
to 4˚C would result in death due to insufficient time for regulating heat loss to skin and 
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activation of the NST. Adaptation of one week is mandatory for wild-type mice to 
allow sufficient time for the mice to activate their NST. Knock-out mice such as UCP1-
/- mice are incapable of NST, therefore they require at least three weeks of adaptation at 
18˚C before transferring them to cold. During cold exposure experiments, ethical and 
humane considerations should be thoroughly reviewed to ensure the wellbeing of mice.  
  
Whole mount antibody staining and immunohistochemistry 
Hematoxylin and Eosin staining (H&E stain) is widely used in basic research 
laboratories as well as in clinical medical diagnosis to visualize and to diagnose 
different stages in cancer progression. Paraffin embedded tissues are rehydrated with 
decreasing concentrations of ethanol, cell nuclei are stained blue with hematoxylin and 
the cytoplasm are counterstained with eosin which gives a pink staining (Paper I, II, IV). 
 Whole mount staining and immunohistochemistry (IHC) methods are essential to 
analyze the angiogenesis effect and the inhibitory effect of anti-angiogenic drugs, as 
well as the expression of proteins in tissues of interest. Whole mount staining and 
immunohistochemistry methods were performed as described in (Paper III). Tumor or 
fat samples were freshly fixed in 4% paraformaldehyde (PFA) (Sigma-Aldrich), 
embedded in frozen O.C.T compound (Sakura Tissue-Tek) followed by whole mount 
staining or immunohistochemical stainings of paraffin embedded sections or 
cyrosections. These methods utilize suitable antibodies that bind to specific antigens 
and these signals can be visualized with fluorescence-labeled secondary antibodies. 
Primary antibodies specific for ECs such as mouse CD31-specific rat antibody (1:200 
whole mount or 1:400 in IHC, BD Pharmingen), mouse CD34-specific rat antibody 
(1:400, Angio-proteomie), mouse endomucin-specific rat antibody (1:400, 
eBiosciences) and biotinylated isolectinB4 (1:500, Vector Lab) were used (Paper I, II, 
III). Antibodies specific to α-SMA (1:400, DAKO), NG2 (1:400, Chemicon) were co-
stained with endothelial specific markers to investigate the interaction of mural cells in 
association to vasculature. Antibodies specific to Ki67 (1:1000, Novocastra), Ter119 
(1:100, BD Pharmingen), EPO (1:100, Santa Cruz Biotech) (Paper I) were used and 
IHC sections were counterstained with an antifade reagent washed DAPI (4',6-
diamindio-2-phenylindole, Vector Lab) to localize the nuclei and to allow us to keep 
the samples for months. In some cases, imaging was performed using a Nikon D 
eclipse C1.  
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Microscopy – importance in biomedical research  
Imaging was performed using fluorescence or confocal microscopy. Confocal imaging 
enables the projection of individual layers of image to obtain a three dimensional image 
that allows us to investigate the vascular structure and the interaction of vascular cells 
with mural cells. Whole mount staining works on tissue samples as thick as 1 mm, and 
the use of confocal microscopy makes it possible to obtain images of greater detail. 
However, whole mount staining requires longer staining procedures and higher 
concentration of antibodies in comparison to cryosection or paraffin immunostaining. 
In constituent papers discussed in this thesis, we quantify the signals obtained from 
antibody staining performed using Image J or Adobe Photoshop to study angiogenesis 
and distribution of mural cells in tumor environment and fat tissue. Even though the 
vascular density of tumor mass is not used as a criterion to access the response to anti-
angiogenic drug in the clinical setting, it is important to investigate vascular density and 
its association and interaction with perivascular and stromal compartments of the tumor 
as a way to study the underlying mechanism of angiogenesis in tumor 
microenvironment and fat tissue.     
 
Fluorescence-activated cell sorting (FACS)  
FACS allows the detection of different types of fluorescently labeled cells based on 
size (forward scatter), and granularity (side scatter) as they flow through a fluid stream. 
Liver and spleen tissues were harvested from mice mechanically minced and filtered 
through with a cell strainer. Blood was collected from the heart, and single cell 
suspensions were prepared. One million cells were blocked with mouse serum and 
incubated with PE-Ter119 (eBioscience) for 20 minutes on ice. Cells were washed with 
PBS and fixed in 1% PFA containing DRAQ5 (Alexis). In this thesis, flow analysis 
was performed by FACSort and analyzed with CellQuest (Paper I).  
 
Complete blood count test  
A complete blood count test is a commonly used in the clinics to diagnose conditions 
such as anemia, RBC count, hemoglobin (HGB) and hematocrit (HCT) levels, infection 
and leukemia (WBC level). Towards the late stages of malignancy, patients usually 
develop cancer-associated syndrome including impairment of several organs. The 
impairment in organs such as kidney and bone marrow affects the RBC and WBC 
population. In this thesis, complete blood count tests were performed using Mindray 
auto hematology analyzer. Approximately two drops of blood were removed from the 
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tail vein and blood count test includes RBC, HGB, HCT and WBC (Paper I, II). The 
hematology analyzer is both time and cost effective in comparison to manual cell 
counting; however, the machine may not be able to differentiate the cell types 
accurately due to cell clustering.   
 
Transduction of specific plasmid, siRNA and shRNA interference  
To elucidate protein function and interaction, gain and loss of function techniques are 
essential to substantiate the findings. In this thesis, angiogenic growth factors were 
overexpressed in selected target cell lines through transduction with retro or lenti-virus 
encoding the growth factor of interest (Paper I, II). In in-vitro knock down experiments, 
small interfering RNAs against mouse Atf3, Klf5, Jun, Sp1, Pdgfra or Pdgfrb were used 
(Dharmacon RNAi Technologie) (Paper II).  
 
Elisa  
Enzyme-linked immunosorbent assay (Elisa), compared to other immunoassays are 
highly specific and sensitive to detect protein. In this thesis, we measure circulating 
levels of soluble VEGFR-1, PDGFBB, EPO (Paper I, II) using sandwich Elisa.   
 
Vascular permeability assays 
Several assays are available to access the perfusion and permeability of vessels. Miles 
permeability assay is a classical method to investigate vascular permeability performed 
by injecting Evan’s blue dye into the tail vein of the mouse, followed by measuring the 
extravasated dyes by spectrophotometer. However, this method is not very accurate and 
usually produces high variation. To obtain accurate ultrastructure of the endothelium, 
labeled bioparticles such as ferritin and colloidal gold particles can be injected, 
followed by detection using electron microscope. However, this method is expensive 
and time consuming. Fluorescent-labeled molecule such as lysine fixable dextran of 
different molecular weights (70 kDa or 2 000 kDa) can be preinjected into mice 
intravenously, and circulate in the vessels before sacrificing the mice. Tissues of 
interest are then fixed in 4% PFA, followed by whole mount staining with anti-CD31 
antibody to evaluate permeability and perfusion respectively (Paper III). 
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4 RESULTS  
This thesis consists of four papers, which represent a concerted effort to understand the 
role of angiogenesis in tumor (Paper I and Paper II) and adipose tissue (Paper III and 
IV).   
 
4.1  PDGF-BB MODULATES HEMATOPOIESIS AND TUMOR 
ANGIOGENESIS BY INDUCING ERYTHROPOIETIN PRODUCTION IN 
STROMAL CELLS (PAPER I) 
In our investigation to unravel the roles of PDGF-BB in tumor angiogenesis and its 
tumor environment, we implanted two different cell lines (fibrosarcoma (T241) and 
Lewis Lung Carcinoma (LLC)) overexpressing PDGF-BB into mice dorsally. We 
observed that PDGF-BB overexpressed tumors grew significantly faster than control 
tumors in both tumor cell lines (Figure 1a). Excision of tumor followed by 
immunohistological staining with several antibodies including ECs specific anti-CD31, 
isolectinB4, and vessels perfusion with dextran revealed that the vascular density was 
higher in these PDGF-BB tumors as compared to the controls (Figure 1c).  
 Moreover, we demonstrated using H&E staining that PDGF-BB tumors have 
increased infiltration of the stroma (Figure 1b). We sought to further examine the 
stromal tissue in PDGF-BB tumors by immunohistological staining with antibodies to 
categorize the stromal subtypes. We used antibodies specific to: PDGFR-β, chondroitin 
sulfate proteoglycan 4 (NG2) and alpha-smooth muscle actin (α-SMA) to identify 
pericytes, vascular smooth muscle cells (VSMCs), and myofibroblasts respectively 
(Figure 1b). We clearly showed an increase in the density of PDGFR-β positive 
staining in PDGF-BB overexpressing tumors but not in the control tumors (Figure 1e), 
indicating an infiltration of stromal cells in the PDGF-BB overexpressing tumors.  
 We were intrigued by the liver and spleen enlargement in these PDGF-BB tumor-
bearing mice when we performed necropsy analysis. Hepatosplenomegaly suggested 
possible hematopoiesis occurring in the liver and spleen. Regular H&E histology 
stainings also showed expansion of red and white pulp in the spleen and presence of 
hematopoietic foci in liver of PDGF-BB tumor-bearing mice. We next investigated 
whether the erythroblasts in these hematopoietic foci were actively proliferating by co-
staining with antibodies specific to Ki67 and Ter119 in the livers and spleens of PDGF-
BB tumor-bearing mice (Figure 1g, h). Indeed, an increase in the Ki67 and Ter119 
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double positive population in the liver and spleen of PDGF-BB tumor-bearing mice 
was observed (Figure 1i, j). We have also evidently showed that PDGFR-α and 
PDGFR-β positive stainings are in the stromal compartment instead of hepatocytes and 
splenocytes of the liver and spleen (Figure 2g-i). The data collectively showed that the 
implantation of tumor cells overexpressing PDGF-BB led to systemic effects such as 
enlargement of liver and spleen, suggesting that tumor-derived PDGF-BB enters the 
circulation and it exerts its effect on peripheral organs. As such, we measured the 
circulating plasma level of PDGF-BB, and a level of 1.2 ng/ml was detected in PDGF-
BB overexpressing tumor-bearing mice (Figure 1f). 
 We next characterized the erythroblasts populations to further confirm that 
hematopoiesis is caused by extramedullary hematopoiesis in the liver and spleen using 
fluorescence-activated cell sorting (FACS). We demonstrated the increased in RBC 
precursor population of erythroid burst forming units (BFU-Es) and mature BFU-Es in 
PDGF-BB tumor-bearing mice by colony forming assay (Figure 2). These results 
showed that PDGF-BB indeed induce extramedullary hematopoiesis but not 
hematopoiesis in bone marrow.   
 To further investigate the effects of extramedullary hematopoiesis, we measured 
the complete blood count in mice. Interestingly, in PDGF-BB tumor-bearing mice, the 
levels of RBC, HCT and WBC were significantly higher, suggesting that PDGF-BB 
induced hepatosplenomegaly induces extramedullary hematopoiesis resulting in an 
increase of RBCs and HCT that might the animal protect against tumor-associated 
anemia (Figure 6h). We were particularly intrigued by the increased levels of RBC and 
HCT, which led us to further measure the circulating erythropoietin (Epo) level. Indeed, 
the circulating plasma levels of Epo increased three-fold in PDGF-BB tumor-bearing 
mice (Figure 3b). The endocrine effect of PDGF-BB was further verified with a tumor-
free model. Administration of adenovirus PDGF-BB into mice caused splenomegaly, 
leading to an increase in the circulating plasma levels of Epo, RBC and HCT as seen in 
the tumor model (Figure 6).  
 Treatment of PDGF-BB tumor-bearing mice (Figure 5a-d) and PDGF-BB 
adenovirus (Figure 6a-d) delivered mice with STI571 (Imatinib) and PDGFR-β-specific 
antibody significantly reduced tumor growth rate and vascular density (in the tumor 
model), hepatosplenomegaly, circulating levels of Epo, RBC and HCT. Taken together, 
we show that PDGF-BB exerts its paracrine effect by binding to PDGFR-β on the 
stromal compartment, thereby increasing the expression of EPO and increased 
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angiogenesis. Treatment of PDGF-BB tumor-bearing mice with Epo specific antibody 
also showed significantly reduced tumor growth rate and vascular density suggesting 
the direct effect of Epo on vascular cells (Figure 5d-f). In addition, we performed in-
vitro stimulation of ECs with Epo, which caused proliferation, cell migration and tube 
formation, supporting the direct effect of Epo on vascular cells (Figure 5g, h).  
 Meanwhile, we performed a series of in-vitro experiments to delineate the 
molecular pathways involved. Stimulation of a stromal fibroblast cell line (S17) with 
PDGF-BB led to stromal cells adopting spindle-like fiber morphology (Figure 3a). 
Subsequently, we performed Affymetrix gene array analysis of S17 stromal cells 
treated with or without PDGF-BB and showed that Atf3 was amongst the top up-
regulated transcription factors (Figure 3e, f). However, sequence analysis shows that 
Atf3 binding sites are absent from the EPO promoter region, suggesting that Atf3 could 
elicit its effect by forming a complex (Figure 3g, h). Consistent with this notion, we 
showed using siRNA and chromatin immunoprecipitation (ChIP) assays that upon 
binding of PDGF-BB to PDGFR-β, Sp1 recruited Atf3 and c-Jun thereby promoting 
transcription from EPO promoter (Figure 3i, j).  
 
Figure F.  Mechanisms of PDGF-BB in promoting tumor angiogenesis (adapted from Paper I) 
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In conclusion, our findings can be summarized in the schematic diagram (Figure F) 
where we show that tumor-derived PDGF-BB enters the circulation and binds to 
PDGFR-β stromal cells that are expressed on liver and spleen. PDGF-BB causes an 
increase in EPO expression and activates hematopoiesis in the liver and spleen, thereby 
increasing the RBC level, which further supports tumor growth by increasing 
oxygenation. We also demonstrated that Epo protects the host against tumor-associated 
anemia. Epo acts directly on ECs stimulating proliferation, cell migration and tube 
formation.  
 
4.2 ANTI-ANGIOGENIC AGENTS SIGNIFICANTLY IMPROVE SURVIVAL IN 
TUMOR-BEARING MICE BY INCREASING TOLERANCE TO 
CHEMOTHERAPY-INDUCED TOXICITY (PAPER II)  
Chemotherapy is widely used in the treatment of cancers. Chemotherapy may be given 
as combination therapy, and can also be administered at different stages of cancer 
development. Another example is the neoadjuvant chemotherapy, where other 
procedures such as surgery are employed after the tumor has been shrunk. However, 
chemotherapy causes a plethora of side effects such as myelosuppression, anemia, hair 
loss and inflammation of the gastrointestinal tract107,156. Cancer patients usually suffer 
from cancer-associated systemic syndrome towards the late stage of cancer malignancy 
including impairment of the bone marrow, anemia, and multiple organs dysfunction157-
160. Thus, chemotherapy delivery on these patients with cancer-induced bone marrow 
function impairment could further impair their bone marrow leading to a more 
detrimental effect. Therefore, we hypothesized that neoadjuvant therapy of anti-
angiogenic drug following chemotherapy could protect the bone marrow from 
chemotherapy induced bone marrow suppression.  
 To investigate this, we established a B16 melanoma mouse tumor model treated 
with an anti-angiogenic drug sunitinib, followed by a chemotherapeutic drug, 
carboplatin. Even though administration of sunitinib alone did not reduce tumor 
volume in B16 tumor-bearing mice, more importantly it did not cause any death 
(Figure 1a, b). This reflects the clinical scenario that anti-angiogenic drug improves 
overall survival. However, delivery of chemotherapy such as carboplatin, to these mice 
resulted in significant reduction of survival rate, where only 20% survival rate was 
observed after 10 days treatment with carboplatin (Figure 1b), suggesting the side 
effects of chemotherapeutic drugs. H&E staining on the bone marrow displayed severe 
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depletion of bone marrow hematopoietic niches, suggesting that chemotherapy, when 
used alone, decreased overall survival via bone marrow suppression (Figure 1e-g).  
Next, we asked if pretreatment with an anti-angiogenic drug could reverse the 
high death rate caused by chemotherapy. We pretreated B16 tumor-bearing mice with 
sunitinib for five days followed by delivery with carboplatin alone, or a combination 
treatment of carboplatin and sunitinib, and observed that pretreatment with sunitinib 
significantly improved the survival rate (Figure 1d). In addition, pretreatment with 
sunitinib followed by carboplatin improved the bone marrow hematopoietic niches. 
Since chemotherapy causes myelosuppression leading to anemia, we sought to measure 
the complete blood count in mice receiving different regimens. Expectedly, tumor-
bearing mice receiving carboplatin alone showed significant decrease in the levels of 
RBC, HGB and WBC. In contrast, sunitinib treatment neither caused suppression of 
hematopoietic niches nor decreased levels of RBC, HGB and WBC, indicating that 
sunitinib could have a protective effect on bone marrow (Figure 1h-j). 
 We have shown previously that high circulating levels of VEGF in tumor-bearing 
mice resulted in several cancer associated systemic syndrome, especially bone marrow 
suppression158. Due to the side effects of chemotherapy, we postulated that 
chemotherapy treatment of mice with bone marrow impairment would synergistically 
suppress the bone marrow function. Thus, we hypothesized that pretreatment with 
sunitinib to VEGF-induced hematopoietic niches suppressed mice could reverse and 
improve synergistic bone marrow suppression caused by VEGF and chemotherapeutic 
drugs. To validate this, we injected tumor cell line with overexpression of VEGF165 to 
mice and treated them with sunitinib. Administration of sunitinib to VEGF tumor-
bearing mice not only improved survival rate (Figure 2b, d), it restored bone marrow 
hematopoietic niches (Figure 2e, f) thereby alleviating the anemic syndrome (improved 
RBC and HGB levels) (Figure 2g-i). As expected, treatment of VEGF-induced bone 
marrow impair tumor-bearing mice with carboplatin dramatically suppressed the bone 
marrow of VEGF tumor-bearing mice (Figure 3a, c-g). We validated the impact of 
chemotherapeutic drug with another widely used chemotherapy drug 
cyclophosphamide (CTX). Conceivably, CTX decreased the survival rate and inhibited 
bone marrow hematopoiesis suppression, demonstrating the general side effect of 
chemotherapy (Figure 3b).  
 We speculated that anti-angiogenic drug could improve survival rate and VEGF 
or chemotherapy impaired bone marrow hematopoietic niches. These VEGF tumor-
bearing mice received either a combination of carboplatin and sunitinib from the 
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beginning, or were first pretreated with sunitinib, followed by buffer, or carboplatin 
alone, or a combination of sunitinib and carboplatin. Expectedly, sequential regimen of 
pretreatment with sunitinib followed by chemotherapy improved hematopoiesis and 
anemia (Figure 4). Surprisingly, pretreatment with sunitinib followed by combination 
therapy of sunitinib and carboplatin did not rescue the bone marrow impairment.  In 
clinical settings, anti-angiogenic drugs and chemotherapeutic drugs are administrated 
simultaneously. Here, our findings demonstrate that pretreatment with sunitinib can 
protect the bone marrow against chemotherapy-induced toxicity, and improve survival. 
Therefore, we propose a different regimen for anti-angiogenic and chemotherapy in 
cancer patients, especially in cancer patients with high circulating VEGF level.  
 Figure G provides a schematic summary on how anti-angiogenic drug protects 
bone marrow suppression and improves survival. Tumor produced VEGF acts directly 
on ECs to promote its survival, proliferation and migration, hence inducing tumor 
angiogenesis and tumor growth. VEGF also enters the blood circulation and target 
peripheral organs such as bone marrow, which causes hematopoiesis and myelogenesis 
suppression. Similarly, chemotherapy drugs also cause impairment in hematopoiesis 
and myelogenesis. If chemotherapeutic drugs are administrated to cancer patients with 
high circulating VEGF level, it will result in a synergistic detrimental impairment of 
bone marrow. However, if an anti-angiogenic drug is administered before the 
chemotherapeutic drug, the angiogenic drug could prime the bone marrow and improve 
bone marrow tolerance to chemotherapy-induced toxicity.   
   
Figure G. Mechanisms underlying anti-angiogenic and cytostatic drugs (adapted from Paper II) 
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4.3 ADIPOSE ANGIOGENESIS: QUANTIFICATION METHODS TO STUDY 
MICROVESSEL GROWTH, REGRESSION AND REMODELING IN VIVO 
(PAPER III)  
Similar to pathological conditions such as tumor angiogenesis (Paper I and II), blood 
vessels are spatiotemporally coupled to the expansion and regression of adipose 
tissues115. Adipose tissue remains highly plastic throughout life, with the capacity to 
increase and decrease its mass up to 10-fold120. This expansion and regression is highly 
dependent on vascularization. The protocol that we have established enables the 
investigation of blood vasculatures in the white adipose tissue (WAT) and interscapular 
brown adipose tissue (iBAT) in association to adipocytes. These detailed procedures 
give a robust and a reliable method to investigate microvessel growth, regression and 
remodeling using mouse model.  
 We established a detailed step-by-step protocol including all the materials and 
reagents used, and a troubleshooting table that includes most of the commonly 
encountered problems during preparation and staining of adipose tissue sections. In this 
protocol, we used WAT and iBAT of C57Bl/6 wt and FOXC2 transgenic mouse strains 
exposed only to room temperature. However, the immunohistological staining methods 
can also be used on adipose tissues of other mouse strains under different conditions 
such as exposure to thermoneutral temperature (30˚C) and cold (4˚C) (see Paper IV and 
Reference 159). 
  We described three different staining methods: whole mount staining, 
immunohistochemical (IHC) staining on cyrosections and paraffin tissue sections that 
revealed the blood vasculature in WAT and iBAT. Whole mount staining is preferred 
over IHC stainings when investigating the three-dimensional structure of blood vessels 
in association to vascular smooth muscle cells is required. IHC is preferred over whole 
mount staining when it is needed to reveal the interaction on the single cell level, and to 
quantify the number of vessels per adipocyte.   
 Slight modifications can be made to this protocol. For example, BODIPY used to 
stain lipid droplets in adipose tissue to identify adipocytes can be replaced with guinea-
pig anti-mouse perilipin antibody (1:400 in PBST) (Procedure 7(A) ix), followed by 
secondary antibody, fluorescence Alexa 647 labeled hamster anti guinea-pig (1:400 in 
PBST) (Procedure 7(A) xii). Costaining with a rat anti-mouse F4/80 antibody or a rat 
anti-mouse Iba1 antibody with LYVE-1 antibody can be used to identify LYVE-1 
positive inflammatory cells in adipose tissues. The subpopulation of M2 macrophages 
can also be characterized using a rat anti-mouse CD206 antibody.  
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4.4 HYPOXIA-INDEPENDENT ANGIOGENESIS IN ADIPOSE TISSUES 
DURING COLD ACCLIMATION (PAPER IV)  
Independent research groups have demonstrated that cold activates an increase in 
metabolic activity in iBAT but no one has investigated the role of blood vessels in this 
cold-activation. We hypothesized if cold would switch on an angiogenic phenotype. If 
so, what are the mechanisms involved in this cold-induced phenotypic change?  
We acclimatized two groups of mice at two temperatures, one group at their 
thermoneutral temperature 30˚C and the other group at 4˚C. We performed necropsy 
analysis of mice exposed to 4˚C and 30˚C for five weeks, and observed an obvious 
change in color of inguinal white adipose tissue (iWAT) (Figure 1a). We asked if this 
gross macroscopic change in adipose tissue was attributed to the increase in blood 
vessels density. We then performed immunohistochemical staining on these tissues 
with ECs specific marker, anti-CD31 and anti-isolectinB4 antibodies. Indeed, we 
observed a significant increase in the density of microvessels in iWAT and iBAT of 
4˚C exposed group (Figure 1 c-h). We did a regular H&E histology staining and were 
intrigued by morphological changes seen in the iWAT and iBAT of 4˚C exposed group 
(Figure 1b). Multilocular droplets with high cellular content usually only observed in 
iBAT were now present in the iWAT of the mice exposed to 4˚C. We further stained 
these tissues with an antibody against prohibitin and observed a significant increase in 
the number of prohibitin positive mitochondria in the iWAT of the 4˚C exposed group. 
These data evidently suggested that exposure of mice to 4˚C caused increased vascular 
density and increased mitochondria content in the iWAT. Next, we asked if these 
increased vessels in the iWAT of the 4˚C exposed group were actively proliferating. 
Immunohistological staining of iWAT of 4˚C and 30˚C exposed to one week with a 
proliferating marker Ki67, and an ECs marker anti-CD31 clearly demonstrated that 
these vessels were actively proliferating (Figure 2a, b).  
 To further elucidate the molecular mechanisms involved in the angiogenic switch, 
we performed Affymetrix gene array on the iWAT of 3 groups of mice exposed to 
30˚C, 4˚C for one week and five weeks. The four most upregulated genes in iWAT of 
4˚C exposed groups were Elovl3, Ucp1, Fabp3 and Cpt1b (Figure 3a, b). These genes 
are usually strongly associated to BAT rather than WAT, suggesting that cold exposure 
resulted in a change in gene expression towards BAT. We showed with Northern blot 
that UCP1, a BAT specific marker was increased more than 500-fold in iWAT after 
one week exposure to 4˚C. It should be emphasized that Vegfa was significantly 
upregulated after one week exposure to 4˚C, but after longer exposure of five weeks the 
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expression level reverted the level back to that of 30˚C. We were intrigued by the 
transient upregulation of VEGF. We further validated this transient increased VEGF 
expression with northern blot and indeed, one week of exposure at 4˚C led to a two-fold 
increase in VEGF (Figure 3f). We also observed a transient upregulation of peroxisome 
proliferator-activated receptor-gamma coactivator-1alpha (PGC-1α) after one week of 
cold exposure. In contrast, an angiogenesis related inhibitor, TSP was significantly 
downregulated after cold exposure (Figure 3b). Similarly, the level of PGC-1α  was 
validated by qRT-PCR (Figure 3c).  
 Since Vegfa and Epas1 (HIF2) expressions were found to be upregulated in 
Affymetrix gene array analysis, we were interested in understanding the role of hypoxia 
in cold-induced angiogenesis. We measured tissue hypoxia using a hypoxyprobe stain 
(pimonidazole), and there was no evidence of hypoxia in iWAT and iBAT of mice 
living at 30˚C (Figure 4). However, in iWAT and iBAT of mice exposed to 4˚C, we 
saw hypoxia especially in the iBAT of mice exposed to 4˚C. We sought to look at role 
of UCP1, a BAT specific protein essential for thermogenesis, in cold-induced 
angiogenesis. We housed UCP1 ablated mice at 4˚C, and used hypoxyprobe and vessel 
staining with anti-CD31 antibody to show that there was no obvious detection of 
hypoxia in iWAT and iBAT. In addition, cold-induced angiogenesis was not observed 
in the iWAT and iBAT of mice exposed to 4˚C. This demonstrated that cold-induced 
angiogenesis is hypoxia independent.  
 We set out to ask which of the two VEGF receptors was responsible for the 
increased angiogenesis seen after cold exposure. VEGFR-1 and VEGFR-2 neutralizing 
antibodies were injected to 4˚C exposed mice. VEGFR-2 antibody, and sunitinib 
administration, followed by whole mount staining with the endothelial specific anti-
CD31 antibody clearly showed decreased vascular density in iWAT and iBAT of mice 
exposed to 4˚C. In contrast, VEGFR-1 antibody treatment exhibited opposing effect. 
This data evidently show that cold-induced angiogenesis was triggered by 
VEGF/VEGFR-2 signaling pathway while VEGFR-1 inhibits cold-induced 
angiogenesis (Figure H).  
 32 
 
                        
Figure H. Cold-induced angiogenic signaling pathway in adipose tissue (adapted from Paper IV) 
 
Surprisingly, treatment with VEGFR-2 antibody caused behavioral alterations. Mice 
that received VEGFR-2 antibody seemed to be less tolerable to cold; as they 
accumulated more nesting materials, preferred to stay in their nest and shivered more 
than the VEGFR-1 antibody administrated mice (Figure 6a, b). These behavioral 
alterations stimulated us to ask if tissue metabolism was altered in cold exposed mice 
treated with VEGFR-1 and VEGFR-2 antibodies. Mice that received VEGFR-2 
antibodies had a lower and a delayed response to NE injection, suggesting that 
VEGFR-2 inhibited neovascularization, hence decreasing the capacity to NST. In 
contrast, administration of VEGFR-1 antibody led to an even higher NE response in 
comparison to the buffer treated group, which clearly show the opposing role of 
VEGFR-1 in cold-induced angiogenesis.  
 33 
 
5 DISCUSSION  
In this thesis, we established two mouse models: 1) tumor-bearing mouse model to 
study the local and systemic impact of tumor-derived factors: PDGF-BB (Paper I) and 
VEGF (Paper II), 2) cold exposed mouse model to unravel the signaling pathways that 
mediate the cold-induced angiogenic switch in white to brite transition in adipose tissue 
(Paper IV).   
In Paper I, we implanted PDGF-BB overexpressed tumor cell lines into mouse 
dorsally and demonstrated how PDGF-BB signaled through the stromal compartment 
of the tumor microenvironment to promote tumor growth and angiogenesis. In Paper II, 
we investigated how VEGF-A led to a synergistic suppression of bone marrow 
hematopoiesis on bone marrow impaired mice that have undergone chemotherapy. We 
then proposed that neoadjuvant therapy with sunitinib before chemotherapy could have 
a protective effect and allow the recovery of cancer-induced bone marrow suppression 
caused by VEGF-A.  
In Paper III, we developed a novel and detailed protocol to study angiogenesis in 
adipose tissue. In Paper IV, we acclimated mice at lower temperature, which activated 
the cold-induced angiogenic switch in iWAT. Further treatment with either VEGFR-2 
antibody or sunitinib inhibited angiogenesis and regulated metabolism, demonstrating 
that VEGF/VEGFR-2 signaling is involved in cold-induced angiogenesis. The cold-
activated angiogenic switch in the iWAT of mice resulted in increased vasculature, as 
well as higher expression of brown-tissue specific proteins, such as UCP1 and PGC-
1α161.  
There have been arguments that using genetically similar and homogenously 
inbred mice is not ideal as a cancer model to recapitulate the effect of drug blockade in 
human. One of the key arguments is the rapid tumor formation in syngeneic and 
xenograft models that have little variations resulting in high reproducibility, which do 
not adequately reflect the tumor heterogeneity and complexity associated with tumor 
microenvironment in cancer patients. The method of determining the response and 
effect of anti-cancer drugs in mouse xenograft models include analyzing parameters 
such as tumor growth rate, tumor volume, retardation and percentage of inhibition of 
tumor growth rate, which differs from that in cancer patients where overall survival and 
cancer progression-free survival are used as benchmarks162. This discrepancy can be 
seen by most of the positive data from many drugs that have been tested in mice 
throughout the years, which during later stages of clinical trials in humans have failed 
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to have any significant effect in prolonging the life of cancer patients. In the recent 
years, more and more researchers are trying to shift the current syngeneic and xenograft 
mouse models toward orthotopic mouse models. Orthotopic mouse models may be 
more time consuming as they require surgery and skillful tumor inoculation techniques, 
however this results in a model that might better represent the condition in cancer 
patients. Unfortunately, there are still no models that exist to study tumor angiogenesis 
and the responses to drugs therefore it is important that we researchers do not 
overestimate the therapeutic outcome of drugs that are tested in mouse models. 
 
5.1 PDGF-BB MODULATES HEMATOPOIESIS AND TUMOR 
ANGIOGENESIS BY INDUCING ERYTHROPOIETIN PRODUCTION IN 
STROMAL CELLS (PAPER I) 
We demonstrated that tumor-derived PDGF-BB binds to PDGFR-β cells in the stromal 
compartment, and mediates transcription factor Atf3 to form a complex with c-Jun and 
Sp1, thereby driving the expression of Epo promoter. This PDGF-BB mediated Epo 
production stimulated angiogenesis and tumor growth. Extramedullary hematopoiesis 
seen in the liver and spleen resulted in increased oxygenation through elevation of RBC, 
HGB and HCT levels further supporting tumor growth. We showed that PDGF-BB 
tumor-bearing mice have a circulating PDGF-BB plasma level of 1 ng/ml, which is 
clinically relevant to patients stricken with cancer such as glioblastoma, lymphoma, 
sarcoma and epithelial cancers163,164. Therefore, we proposed that treatment with anti-
PDGF-BB drugs and anti-Epo drugs would yield better effects, especially in cancer 
patients with high circulating levels of PDGF-BB.  
However, anti-Epo treatments with patients in the clinic may be controversial as 
Epo is an erythropoiesis-stimulating agent that is used in clinics to treat patients with 
chronic renal failure and cancer-induced anemia48-51,165-167. Using rhEpo as a treatment 
for patients with renal failure led to severe side effects, including cardiovascular 
complications and stroke167. In addition, rhEpo administration to cancer-induced 
anemic patients caused thromboembolism168. With evidence that the use of Epo in 
patients may lead to the stimulation of underlying small tumor masses, we proposed the 
use of anti-Epo to cancer patients169. However, due to unknown adverse effects that 
may be caused by anti-Epo delivery in cancer patients, the use of anti-Epo as a 
treatment requires more investigation53,170.  
Several drugs targeting the PDGF signaling pathway have been approved by the 
FDA and are currently used as treatment for different types of cancers by targeting the 
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autocrine signals in tumor cells171,172. It is known that PDGF-BB is essential for 
pericytes recruitment that aids the maturation and stability of vessels. Therefore would 
inhibit the PDGF signaling result in leaky vessels with poor pericyte coverage, thereby 
facilitating metastasis? It was demonstrated recently that anti-PDGF (Imatinib mesylate) 
treatment in low PDGF-BB producing tumor led to increased tumor cell dissemination 
and metastasis, whereas treatment in high PDGF-BB producing tumor prevented 
vascular leakage and decreased tumor dissemination and metastasis47.   
In Paper I, we demonstrated that the administration of anti-Epo antibody to 
PDGF-BB tumor-bearing mice with high circulating levels of PDGF inhibited tumor 
growth. In conclusion, the use of drugs targeting the PDGF signaling pathway needs to 
be investigated more thoroughly. Based on our study, we speculated that therapy using 
drugs targeting both the PDGF signaling pathway and Epo pathway could be an 
alternative therapy in cancer patients with high circulating levels of PDGF-BB. 
However, the administration of anti-Epo to reduce cancer-induced anemia may raise 
controversial debates, since Epo is used to treat patients suffering from cancer-induced 
anemia48,49,165-167. In conclusion, the use of anti-Epo with the current anti-PDGF therapy 
definitely requires further investigations.  
 
5.2 ANTI-ANGIOGENIC AGENTS SIGNIFICANTLY IMPROVE SURVIVAL 
IN TUMOR-BEARING MICE BY INCREASING TOLERANCE TO 
CHEMOTHERAPY-INDUCED TOXICITY (PAPER II)  
Chemotherapy is widely used in the treatment of cancers. Chemotherapy may be given 
as combination therapy at different stages of cancer development103,156,173. Another 
example is the neoadjuvant chemotherapy, where other procedures such as surgery are 
employed after the tumor has shrunk. However, chemotherapy causes a plethora of side 
effects such as bone marrow suppression, which causes the reduction of RBCs 
production and platelet formation, resulting in bleeding and bruising tendencies. In 
addition, WBC level is also decreased, causing the patients to be susceptible to 
secondary infections.  
Our group has previously reported that high circulating plasma levels of VEGF-A 
in tumor-bearing mice caused severe systemic effects including anemia and the 
depletion of bone marrow hematopoietic niches158. Knowing the adverse impact of 
chemotherapy on bone marrow, we asked if further treatment of these VEGF-induced 
bone marrow impaired mice with chemotherapy would cause a synergistic impairment 
of the bone marrow (Paper II).  
 36 
 
Conventional regime of chemotherapy drug is used as neoadjuvant therapy, or in 
combination with other anti-cancer drugs including anti-angiogenic drugs173. In this 
paper, we proposed an alternative regime where we first treated the cancer-induced 
bone marrow using an anti-angiogenic drug to allow bone marrow recovery before 
administrating the chemotherapy treatment. This protects the bone marrow from 
chemotherapy-induced suppression, thereby improving survival.  
In this study, we used murine melanoma as it produces high levels of VEGF-A, 
thereby mirroring cancer. The choice of chemotherapy drugs (CTX and carboplatin) 
and sunitinib as an anti-angiogenic drug was based on the accessibility to the drugs. 
Therefore, it would be interesting to validate our findings using human cell lines that 
produce high levels of VEGF naturally, and to use the relevant chemotherapy drugs 
that have been approved clinically for the treatment against the different types of cancer. 
Nevertheless, we have demonstrated that pretreatment with an anti-angiogenic drug 
followed by a sequential delivery of chemotherapy would yield better survival than 
combination therapy.  
 
5.3 HYPOXIA-INDEPENDENT ANGIOGENESIS IN ADIPOSE TISSUES 
DURING COLD ACCLIMATION (PAPER IV)  
The expansion and regression of adipose tissue throughout life is highly dependent on 
angiogenesis and the remodeling of blood vessels. Alterations in vasculature to 
modulate the supply of oxygen, nutrients and metabolites may be an effective 
therapeutic intervention for obesity and its related metabolic disorders. We developed a 
detailed protocol to study the vasculature in adipose tissues (Paper III), and further 
extended the protocol to study the role of vasculature in adipose tissue and adipose 
tissue metabolism174. 
In this study, we demonstrated that it was the angiogenic switch in adipose tissue 
that modulated the cold-induced iWAT to brite adipose tissue transformation. Organ 
vasculature is dependent on its metabolic status, as shown by the great number of blood 
vessels in the highly metabolically active BAT so as to provide the tissue with 
sufficient metabolites. Cold acclimation not only further increased vascular density in 
BAT to support its demand for oxygen during NST, it also increased vasculature in 
iWAT. In addition, cold acclimation caused iWAT to acquire the characteristics of 
BAT. In this paper, we show that cold-stimulated angiogenesis is highly mediated by 
the VEGF-A/VEGFR-2 signaling pathway. Anti-VEGF pathway drugs, specifically 
sunitinib and VEGFR-2 antibody, could inhibit the cold-induced angiogenic switch.  
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Administration of VEGFR-1 antibody on the other hand, caused an opposite effect 
where blood vasculature was increased and an increased response upon NE stimulation.  
What other pro-angiogenic factors are essential in the modulation of angiogenesis 
in adipose tissues? Obese individuals usually have high circulating serum levels of 
VEGF, therefore administration of anti-angiogenic drugs such as anti-VEGF have been 
speculated to reduce hypertrophy and fat accumulation. Anti-angiogenic drugs have 
been used in mouse models to reduce adipose tissue mass however, administrating such 
drugs to human patients require more investigations. We speculate if it is possible to 
use pro-angiogenic factors such as VEGF to increase blood vasculature before 
subjecting obese individuals to the cold as a treatment against obesity. The pretreatment 
of VEGF would ensure the provision of sufficient nutrients and metabolites to support 
the WAT to brite transition. 
In our cold acclimation mouse model, we showed that cold exposure transformed 
iWAT depot to brite adipose tissue that exhibits the high metabolic prolife usually seen 
in BAT. What about the intra-abdominal adipose tissues in cold exposed mice such as 
the gonadal, omental, and mesentery WAT? The ability to transform these “pure” intra-
abdominal WAT to adopt a brite-like profile is more closely related to the clinical 
settings because it is the accumulation of visceral rather than subcutaneous fat that is 
more associated to obesity-related metabolic diseases. Independent groups have 
demonstrated that short-term exposure of adult individuals to the cold increases the 
FDG uptake in BAT (see 1.3.5). It will be of interest to investigate if the blood 
vasculatures in the WAT and BAT of these individuals are similar to that seen in our 
mouse model. 
Our group has recently shown that with cold exposure, two of our genetic 
knockout mice, more specifically the apolipoprotein E knockout and low-density 
lipoprotein knockout strains, showed increased atherosclerotic plaque growth and 
instability due to the activation of UCP1 dependent lipolysis175. Therefore, close 
monitoring is required for this method of using cold exposure to increase the 
metabolism in obese individuals especially those with underlying pre-atherosclerotic 
plaques as they risk suffering from atherosclerotic-associated myocardial infarction or 
even stroke.  
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6 CONCLUSION 
  
• Paper I: Tumor-derived PDGF-BB promotes tumor growth, angiogenesis and 
extramedullary hematopoiesis. PDGF-BB binds to PDGFR-β on stromal and 
perivascular cells and induces Epo expression, which accelerates tumor 
growth by stimulating endothelial cell proliferation, migration, sprouting and, 
tube formation. Moreover, extramedullary hematopoiesis-induced 
oxygenation supports tumor growth and serves as a protection against tumor-
associated anemia.   
• Paper II: Chemotherapy delivery to tumor-bearing mice with high circulating 
VEGF levels further suppresses bone marrow hematopoiesis. However, 
chemotherapy-induced bone marrow suppression can be rescued by 
pretreatment with the anti-angiogenic drug, sunitinib, followed by sequential 
delivery of chemotherapy drugs CTX and carboplatin. 
• Paper III: We developed novel methods to study angiogenesis in adipose 
tissue. 
• Paper IV: Cold exposure leads to activation of angiogenesis in white and 
brown adipose tissues. White to brite-like adipose tissue transformation is 
accompanied by increased expression levels of the brown-fat associated 
proteins, UCP1 and PGC-1α. Cold-induced angiogenesis and metabolic 
change in white and brown adipose tissue can be inhibited by VEGFR-2 
blockade. 
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7 FUTURE PERSPECTIVES 
7.1 CANCER  
“Seeking a cure in cancer in our time” – Barack Obama 
 Scientific knowledge is dynamic where scientific theories and even long-standing 
dogmas are constantly challenged, refined and modified as we gather new data. Cancer 
patients have benefited from the advancement in technology and understanding of the 
disease, which has resulted in more concise early diagnosis, better screening and 
therapies as compared to three decades ago. However, cancer remains to be an enigma 
as shown by the complex process of evading the hosts’ defense mechanisms to best 
exploit, and eventually wear them down. This also means that finding the cure for 
cancer would require a much broader and more complex incorporation of all the 
knowledge that has been gathered over the years. 
 The WHO has projected that the number of newly diagnosed cancer cases 
worldwide will rise from 11.3 million in 2007 to 15.5 million in 2030, while the 
number of deaths from cancer will increase 45% (from 7.9 million to 11.5 million) over 
the same time period. One of the reasons for this jump in numbers is due to growing 
number of over-60s as compared to any other age group in almost every country. Since 
the risk of most types of cancer increases with age, this would translate to a higher 
economic burden on most developed countries in the world that are faced with a higher 
aging population. 
“Disease is the biggest money maker in our economy.” – John H. Tobe   
 It has been estimated that the total medical expenditure on cancer treatment in 
Western Europe would increase by 15% in 2014. Many pharmaceutical companies are 
investing more into research and development of oncology drugs. This increasing 
attention on cancer research has also proven to be beneficial with the exponential 
advancement in development of medical oncology techniques. It was predicted that by 
the year 2058, 95% of all cancers could be controllable176.  
Taking metastatic colorectal cancer (MCC) as an example, the overall survival of 
MCC has almost doubled in a span of 15 years compared to a few decades ago when 
such a diagnosis, even at stage one, would be equivalent to a death sentence84. The 
advancement in cancer research has allowed us to better understand the genetics and 
other carcinogenic factors. This has also aided the pharmaceutical companies in the 
development of new cancer drugs, biomarkers, sophisticated diagnostic and screening 
tools to facilitate early detection and screening that benefited the cancer patients. 
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However, cancer remains as a sensitive topic to discuss as some types of cancer remain 
difficult to detect and do not have any effective therapy.  
 
7.2 ANTI-ANGIOGENIC THERAPY IN CANCER  
“If you have cancer and you are a mouse, we can take good care of you.” – Judah 
Folkman  
Anti-angiogenesis therapy has become one of the pillars for cancer therapy 
following surgery, chemotherapy and radiotherapy. Anti-angiogenic drugs such as 
bevacizumab have better efficacy when used in combination or as sequential therapy. 
However, these drugs are expensive especially when they have to be used in a 
combination regime. This further implicates economic strains due to the healthcare in 
the society. Even with the vast advancement in research, most patients are still unable 
to benefit from the new drugs because pharmaceutical companies are selling the drugs 
at a high price.  
Again, using MCC as an example, the standard treatment includes using a 
5’Fluorouracil plus leucovorin regime. One could also choose a combination of 
FOLFOX/bevacizumab and Irinotecan, followed by Cetuximab or Irinotecan, which 
has shown to increase life expectancy from 54 weeks to 116 weeks177,178. However, the 
combination regime is also costly, where the total drug cost increases from $4,000 to 
$173,000. The survival advantage of one year would cost $169,000 more. This implies 
that such benefits received from the advancement in cancer drug development will only 
apply to cancer patients from wealthy families or those from countries with better 
healthcare systems. 
Basic science research allows us to better understand the evolution of cancer 
development and eventually find a way to conquer them, or at least to slow down the 
rate of cancer progression. However, not all the cancer patients receive these benefits 
from the current newly developed drugs. One of the reasons is that pharmaceutical 
companies pose to be the limiting step that deters cancer patients from benefiting from 
the new cancer drugs due to their high cost. It is important that pharmaceutical 
companies aim to reduce the overall health costs and improve patients’ health. Another 
limiting factor is that oncologists are unable to keep up with the fast pace of 
development of novel cancer therapies. New oncology drugs that enter the market fail 
to reach the oncologists or cancer patients fast enough.  
 It is also important to identify biomarkers to determine the different patient 
cohorts and administrate the correct combination of drugs to the individual group. 
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Taking the withdrawal of bevacizumab from metastatic HER2-negative breast cancer 
patients as an example, Genentech proposed a phase III clinical trial to include the use 
of a biomarker to better identify the cohort of patients that will have maximum benefit 
with bevacizumab treatment179,180.  Most cancer patients in their late stages of 
malignancy die from metastasis instead of the primary tumor mass. This increases the 
urgency for the development of more sophisticated imaging machines to effectively 
detect metastatic cancer cells, as well as drugs that can inhibit different phases in the 
metastatic cascade. Another emerging problem faced in cancer therapy is drug 
resistance79,80. We need to better understand how cancer cells develop mechanisms of 
resistance to drug treatment.  
Since blood vessels are involved in almost every stages of tumor progression 
including growth and subsequent invasive metastatic cascades, anti-angiogenic drugs 
that inhibit the growth these vessels should provide great therapeutic avenues for cancer 
treatments. Why are we not able to effectively treat all types of cancer with anti-
angiogenic drugs?  
 
7.3 CONCLUDING REMARKS  
“We don’t know a millionth of one percent about anything.” – Thomas A. Edison 
 Cancer is the world’s second leading cause of most deaths in people. Cancer 
drugs unfortunately remain to be expensive, resulting in an economic strain on the 
healthcare systems in most countries. Our knowledge and understanding of the 
functions and mechanisms of cancer progression has increased immensely over the last 
30 years. Yet, new questions arise that pose as challenges for the future. Are we able to 
come up with new drugs? Can we revisit existing therapeutic regimes to outsmart these 
intelligent cancer cells? With all the existing constrains, will we be able to cure cancer 
in our time? 
 
7.4 OBESITY  
The current global problem in obesity and obesity-related metabolic disorders such as 
type II diabetes and cardiovascular disorders are alarming and require immediate 
attention. Last year, the Organization for Economic Co-operation and Development 
(OECD) estimated the health expenditure on obesity to account for 1-3% of total health 
expenditure in most countries. The OECD also projected that two out of three people 
would be overweight or obese in some countries by 2020. In the last five years, the 
OECD has proposed affordable and cost-effective programs that governments can 
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adopt to prevent obesity and overweight. This includes implementing taxes on 
unhealthy food and beverages, as well as increasing health promotion messages 
through media to educate consumers on making healthier food options and also to 
encourage the increase of physical activity. Since childhood obesity is also on the rise, 
the OECD encourages governments to limit unhealthy food advertising to children. 
Would tax implementation on unhealthy food help to curb obesity or would it backfire 
and result in the reduction of healthier options in order to then pay for more expensive 
unhealthy food?  
 
7.5 THERAPEUTIC INTERVENTION FOR OBESITY 
Based on the current insights, the thermogenic activity of BAT is currently regarded as 
the ‘body’s best weapon’ against obesity. As 40-50 g of fully activated BAT can burn 
up to 4 kg of WAT in a year, it highly suggests that increasing BAT activity could be 
used as an intervention for obesity118,137.  Emerging evidence indicates the plausibility 
of using cold exposure to stimulate BAT activity and activate brite transition in adult 
humans136,139,140. In summary, these observations led to the conclusion that BAT 
activity negatively correlates with age and BMI, suggesting that obese individuals 
probably have low BAT activity, cold-induced BAT activation is present in higher 
amount in younger individuals, and BAT is more readily detectable in female 
individuals than in male. Therefore, the identification of novel methods to activate BAT 
and to stimulate browning in WAT will also become more critical, especially in clinical 
trials.  
 It is now apparent that cold exposure is capable of inducing BAT activity in 
individuals, resulting in increased metabolism and energy expenditure110,136,139,140,142,145. 
However, it is noteworthy to mention that precautions should be taken to expose 
individuals with pre-atherosclerotic plaques to cold. It has been recently shown that 
cold exposure led to an increased UCP1 dependent lipolysis leading to instability of 
atherosclerotic plaques175. Apart from cold exposure, there are several potential 
methods that can activate the sympathetic nervous systems and mediate BAT activity, 
such as adrenergic agonists (ephedrine, isoprenaline), capsinoids and insulin143,146. 
These methods seem to be promising and further investigations will be needed to reveal 
their full potential.  
Since adipocytes produce a myriad of adipokines, further elucidation of their 
functions is required to allow us to select better targets to combat obesity and prevent 
obesity-related metabolic diseases. The administration of anti-angiogenic drugs to 
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obese individuals remains controversial due to the differences in metabolic functions of 
WAT and BAT. Anti-angiogenic drugs targeted to WAT should inhibit blood vessels 
growth, thereby restricting their growth and expansion. On the other hand, pro-
angiogenic drugs should be given to obese individuals seeking to increase their BAT 
activity since the increase in angiogenic vessels would translate to more oxygen and 
nutrients to meet the higher metabolic demands during BAT activation. In conclusion, 
the potential of anti-angiogenic drugs against obesity remains controversial and 
requires further investigations.  
 
7.6 CONCLUDING REMARKS 
Obesity and overweight epidemic is escalating, which puts individuals at a greater risk 
for life-threatening diseases, including type II diabetes, and cardiovascular disorders. 
The cause of obesity and overweight can be due to factors including genetics, sedentary 
lifestyle and unhealthy eating habits. Fortunately, adopting a healthier lifestyle such as 
eating better and increasing physical activity can prevent overweight and obesity, even 
for someone who is genetically predisposed to weight gain. Until we uncover the full 
potential of using anti-angiogenic drugs against obesity, adopting a healthier lifestyle 
habits seem to be the most economic and non-invasive approach to curb obesity.  
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